Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 4/2008

01-04-2008 | Review Article

Current Management of Pain Associated with Multiple Sclerosis

Authors: Dr Walter Pöllmann, Wolfgang Feneberg

Published in: CNS Drugs | Issue 4/2008

Login to get access

Abstract

While pain is a common problem in patients with multiple sclerosis (MS), it is not frequently mentioned by patients and a more direct approach is required in order to obtain information about pain from patients. Many patients with MS experience more than one pain syndrome; combinations of dysaesthesia, headaches and/or back or muscle and joint pain are frequent. For each pain syndrome a clear diagnosis and therapeutic concept needs to be established.
Pain in MS can be classified into four diagnostically and therapeutically relevant categories: (i) neuropathic pain due to MS (pain directly related to MS); (ii) pain indirectly related to MS; (iii) MS treatment-related pain; and (iv) pain unrelated to MS.
Painful paroxysmal symptoms such as trigeminal neuralgia (TN), or painful tonic spasms are treated with antiepileptics as first choice, e.g. carbamazepine, oxcarbazepine, lamotrigine, gabapentin, pregabalin, etc. Painful ‘burning’ dysaes-thesias, the most frequent chronic pain syndrome, are treated with TCAs such as amitriptyline, or antiepileptics such as gabapentin, pregabalin, lamotrigine, etc. Combinations of drugs with different modes of action can be particularly useful for reducing adverse effects. While escalation therapy may require opioids, there are encouraging results from studies regarding cannabinoids, but their future role in the treatment of MS-related pain has still to be determined.
Pain related to spasticity often improves with adequate physiotherapy. Drug treatment includes antispastic agents such as baclofen or tizanidine and in patients with phasic spasticity, gabapentin or levetiracetam are administered. In patients with severe spasticity, botulinum toxin injections or intrathecal baclofen merit consideration. While physiotherapy may ameliorate malposition-induced joint and muscle pain, additional drug treatment with paracetamol (acetaminophen) or NSAIDs may be useful. Moreover, painful pressure lesions should be avoided by using optimally adjusted aids.
Treatment-related pain associated with MS can occur with subcutaneous injections of interferon-β or glatiramer acetate, and may be reduced by optimizing the injection technique and by local cooling. Systemic (particularly ‘flu-like’) adverse effects of interferons, e.g. myalgias, can be reduced by administering paracetamol, ibuprofen or naproxen. A potential increase in the frequency of preexisting headaches after starting treatment with interferons may require optimization of headache attack therapy or even prophylactic treatment.
Pain unrelated to MS, such as back pain or headache, is common in patients with MS and may deteriorate as a result of the disease.
In summary, a careful analysis of each pain syndrome will allow the design of the appropriate treatment plan using various medical and nonmedical options (multimodal therapy), and will thus help to improve the quality of life (QOL) of the patients.
Footnotes
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literature
1.
Ehde DM, Gibbons LE, Chwastiak L, et al. Chronic pain in a large community sample of persons with multiple sclerosis. Mult Scler 2003; 9: 605–11PubMedCrossRef
2.
Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis: a 5-year follow-up study. Ital J Neurol Sci 1995; 16: 629–32PubMedCrossRef
3.
Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis. Acta Neurol Scand 1991; 84: 197–200PubMedCrossRef
4.
Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis: prevalence and clinical characteristics. Eur J Pain 2005; 9(5): 531–42PubMedCrossRef
5.
Beiske AG, Pedersen ED, Czujko B, et al. Pain and sensory complaints in multiple sclerosis. Eur J Neurol 2004; 11(7): 479–82PubMedCrossRef
6.
Ehde DM, Osborne TL, Hanley MA, et al. The scope and nature of pain in persons with multiple sclerosis. Mult Scler 2006; 12(5): 629–38PubMedCrossRef
7.
Hadjimichael O, Kerns RD, Rizzo MA, et al. Persistent pain and uncomfortable sensations in persons with multiple sclerosis. Pain 2007; 127(1-2): 35–41PubMedCrossRef
8.
Solaro C, Brichetto G, Amato MP, et al. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. PaIMS Study Group. Neurology 2004; 63(5): 919–21
9.
Pöllmann W, Feneberg W, Erasmus L-P. Pain in multiple sclerosis: a still underestimated problem. The 1-year prevalence of pain syndromes, significance and quality of care of multiple sclerosis inpatients [in German]. Nervenarzt 2004; 75(2): 135–40PubMedCrossRef
10.
Solomon P. Congruence between health professionals’ and patients’ pain ratings: a review of the literature. Scand J Caring Sci 2001; 15: 174–80PubMedCrossRef
11.
Marchettini P, Formaglio F, Lacerenza M. Pain as heralding symptom in multiple sclerosis. Neurol Sci 2006; 27Suppl. 4: S294–6CrossRef
12.
Merskey H, Bogduk N, editors. Classification of chronic pain. 2nd ed. Seattle (WA): IASP Press, 1994
13.
Headache Classification Committee of the International Headache Society. The international classification of headache disorders. 2nd ed. Cephalalgia 2004; 24Suppl. 1: 1–160
14.
Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 2003; 7: 1–124
15.
Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. EFNS Task Force. Eur J Neurol 2006; 13(11): 1153–69PubMedCrossRef
16.
Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65(6): 812–9PubMedCrossRef
17.
Sindrup SH, Jensen TS. Effect of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999; 83: 389–400PubMedCrossRef
18.
Sindrup SH, Jensen TS. Pharmacologie treatment of pain in polyneuropathy. Neurology 2000; 55: 915–20PubMedCrossRef
19.
20.
Kalia LV, O’Connor PW. Severity of chronic pain and its relationship to quality of life in multiple sclerosis. Mult Scler 2005; 11(3): 322–7PubMedCrossRef
21.
Khan F, Pallant J. Chronic pain in multiple sclerosis: prevalence, characteristics, and impact on quality of life in an Australian community cohort. J Pain 2007 Aug; 8(8): 614–23PubMedCrossRef
22.
23.
Ehde DM, Osborne TL, Jensen MP. Chronic pain in persons with multiple sclerosis. Phys Med Rehabil Clin N Am 2005 May; 16(2): 503–12PubMedCrossRef
24.
Osborne TL, Jensen MP, Ehde DM, et al. Psychosocial factors associated with pain intensity, pain-related interference, and psychological functioning in persons with multiple sclerosis and pain. Pain 2007 Jan; 127(1-2): 52–62PubMedCrossRef
25.
Cleeland CS. The brief pain inventory. Pain Research Group. Copyright 1991, Dr Charles Cleeland, Anderson Cancer Center, Pain Research Group, 1100 Holcombe, Houston, TX 77030 (additional information available in: Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994; 23(2): 129–38)
26.
Melzack R. The McGill pain questionnaire: major properties and scoring methods. Pain 1975 Sep; 1(3): 277–99PubMedCrossRef
27.
Heckman-Stone C, Stone C. Pain management techniques used by patients with multiple sclerosis. J Pain 2001 Aug; 2(4): 205–8PubMedCrossRef
28.
Higginson IJ, Hart S, Silber E, et al. Symptom prevalence and severity in people severely affected by multiple sclerosis. J Palliat Care 2006; 22(3): 158–65PubMed
29.
Kümpfel T, Hoffmann LA, Pöllmann W, et al. Palliative care in patients with severe multiple sclerosis: two case reports and a survey among German MS neurologists. Palliat Med 2007 Mar; 21(2): 109–14PubMedCrossRef
30.
Young WF, Weaver M, Mishra B. Surgical outcome in patients with coexisting multiple sclerosis and spondylosis. Acta Neurol Scand 1999; 100: 84–7PubMedCrossRef
31.
Bashir K, Cai CY, Moore TA, et al. Surgery for cervical spinal cord compression in patients with multiple sclerosis. Neurosurgery 2000; 47: 637–42PubMed
32.
Etus V, Akansel G, Ilbay K, et al. Multiple sclerosis and coexisting intradural extramedullary spinal cord tumor: a case report. Neurol Sci 2002; 23: 119–22PubMedCrossRef
33.
Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169–78PubMedCrossRef
34.
Pöllmann W, Feneberg W, Steinbrecher A, et al. Therapy of pain syndromes in multiple sclerosis: an overview with evidence-based recommendations [in German]. Fortschr Neurol Psychiatr 2005; 73(5): 268–85PubMedCrossRef
35.
Feneberg W. Neurogenic bowel dysfunction: In: Henze T, Rieckmann P, Toyka KV. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol 2006; 56 (2): 87–8
36.
Optic Neuritis Study Group. The clinical profile of optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1991; 109: 1673–8CrossRef
37.
Haas DC, Kent PF, Friedman DI. Headache caused by single lesion of multiple sclerosis in the periaqueductal gray area. Headache 1993; 33: 452–5PubMedCrossRef
38.
Feneberg W, Pöllmann W. Headache in multiple sclerosis: a prospective study using the IHS classification criteria [abstract]. J Neurol 2000; 247Suppl. 3: III/179
39.
Pöllmann W, Mayr B, ten Bruggencate G, et al. Cervicogenic headache in multiple sclerosis with cervical spinal demyelination: coincidental or causal? Akt Neurol 2005; 32: 445–50CrossRef
40.
Sellebjerg F, Barnes D, Filippini G, et al. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol 2005; 12(12): 939–46PubMedCrossRef
41.
Rieckmann P, Toyka KV, Bassetti C, et al. Escalating immunotherapy of multiple sclerosis: new aspects and practical application. Multiple Sclerosis Therapy Consensus Group. J Neurol 2004; 251(11): 1329–39PubMedCrossRef
42.
Hellwig K, Lukas C, Brune N, et al. Repeat intrathecal triamcinolone acetonide application reduces acute occurring painful dysesthesia in patients with relapsing remitting multiple sclerosis. ScientificWorldJournal 2006; 6: 460–5PubMedCrossRef
43.
Backonja MM. Use of anticonvulsants for treatment of neuropathic pain. Neurology 2002; 59Suppl. 2: S14–7PubMedCrossRef
44.
Zakrzewska JM, Chaudhry Z, Nurmikko TJ, et al. Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain 1997; 73: 223–30PubMedCrossRef
45.
Fromm GH, Terrence CF, Chattha AS. Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up. Ann Neurol 1984; 15(3): 240–4PubMedCrossRef
46.
Chandra B. The use of clonazepam in the treatment of tic douloureux (a preliminary report). Proc Aust Assoc Neurol 1976; 13: 119–22PubMed
47.
Peiris JB, Perera GL, Devendra SV, et al. Sodium valproate in trigeminal neuralgia [letter]. Med J Aust 1980; 2: 278PubMed
48.
Kanai A, Suzuki A, Kobayashi M, et al. Intranasal lidocaine 8% spray for second-division trigeminal neuralgia. Br J Anaesth 2006; 97(4): 559–63PubMedCrossRef
49.
50.
Solaro C, Lunardi GL, Capello E, et al. An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology 1998; 51: 609–11PubMedCrossRef
51.
Solaro C, Messmer Uccelli M, et al. Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis. Eur Neurol 2000; 44: 45–8PubMedCrossRef
52.
Khan OA. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology 1998; 51: 611–4PubMedCrossRef
53.
Leandri M, Lundardi G, Inglese M, et al. Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis. J Neurol 2000; 247: 556–8PubMedCrossRef
54.
Lunardi G, Leandri M, Albano C, et al. Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia. Neurology 1997; 48: 1714–7PubMedCrossRef
55.
DMKG Study Group. Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis. J Neurol 2003; 250: 542–5CrossRef
56.
Zvartau-Hind M, Din MU, Gilani A, et al. Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology 2000; 55: 1587–8PubMedCrossRef
57.
D’Aleo G, Sessa E, Di Bella P, et al. Topiramate modulation of R3 nociceptive reflex in multiple sclerosis patients suffering paroxysmal symptoms. J Neurol 2001; 248: 996–9PubMedCrossRef
58.
Berk C, Constantoyannis C, Honey CR. The treatment of trigeminal neuralgia in patients with multiple sclerosis using percutaneous radiofrequency rhizotomy. Can J Neurol Sci 2003; 30: 220–3PubMed
59.
Kondziolka D, Lunsford LD, Bissonette DJ. Long-term results after glycerol rhizotomy for multiple sclerosis-related trigeminal neuralgia. Can J Neurol Sci 1994; 21: 137–40PubMed
60.
Pickett GE, Bisnaire D, Ferguson GG. Percutaneous retrogasserian glycerol rhizotomy in the treatment of tic douloureux associated with multiple sclerosis. Neurosurgery 2005 Mar; 56(3): 537–45PubMedCrossRef
61.
Broggi G, Ferroli P, Franzini A, et al. Role of microvascular decompression in trigeminal neuralgia and multiple sclerosis. Lancet 1999; 354: 1878–9PubMedCrossRef
62.
Huang E, Teh BS, Zeck O, et al. Gamma knife radiosurgery for treatment of trigeminal neuralgia in multiple sclerosis patients. Stereotact Funct Neurosurg 2002; 79(1): 44–50PubMedCrossRef
63.
64.
Wiffen P, Collins S, McQuay H, et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev 2005 Jul 20; (3): CD001133
65.
Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain. Cochrane Database Syst Rev 2005 Jul 20; (3): CD005451
66.
Ramsaransing G, Zwanikken C, De Keyser J. Worsening of symptoms of multiple sclerosis associated with carbamazepine. BMJ 2000; 320: 1113PubMedCrossRef
67.
Zakrzewska JM, Patsalos PN. Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia. J Neurol Neurosurg Psychiatry 1989; 52: 472–6PubMedCrossRef
68.
Carrazana E, Mikoshiba I. Rationale and evidence for the use of oxcarbazepine in neuropathic pain. J Pain Symptom Manage 2003; 25(5 Suppl.): S31–5PubMedCrossRef
69.
Solaro C, Restivo D, Mancardi GL, et al. Oxcarbazepine for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study. Neurol Sci 2007; 28(3): 156–8PubMedCrossRef
70.
Schmidt D, Elger CE. How is oxcarbazepine different from carbamazepine [in German]? Nervenarzt 2004; 75: 153–60PubMedCrossRef
71.
Beydoun A. Safety and efficacy of oxcarbazepine: results of randomized, double-blind trials. Pharmacotherapy 2000; 20 (8 Pt 2): 152–8SCrossRef
72.
Solaro C, Brichetto G, Battaglia MA, et al. Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. Neurol Sci 2005; 25(6): 307–10PubMedCrossRef
73.
Obermann M, Yoon MS, Sensen K, et al. Efficacy of pregabalin in the treatment of trigeminal neuralgia. Cephalalgia 2008; 28(2): 174–81PubMed
74.
Lüttmann RJ, Brinkmann B, Loddenkemper T, et al. Misoprostol in the treatment of trigeminal neuralgia in MS patients: a report of three cases [abstract]. Cephalalgia 2000; 20: 382
75.
Reder AT, Arnason BG. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology 1995; 45: 1097–100PubMedCrossRef
76.
Solaro C, Uccelli MM, Brichetto G, et al. Topiramate relieves idiopathic and symptomatic trigeminal neuralgia. J Pain Symptom Manage 2001; 21: 367–8PubMedCrossRef
77.
Gilron I, Booher SL, Rowan JS, et al. Topiramate in trigeminal neuralgia: a randomized, placebo-controlled multiple crossover pilot study. Clin Neuropharmacol 2001; 24: 109–12PubMedCrossRef
78.
Lechin F, van der Dijs B, Lechin ME, et al. Pimozide therapy for trigeminal neuralgia. Arch Neurol 1989; 46: 960–3PubMedCrossRef
79.
Piovesan EJ, Teive HG, Kowacs PA, et al. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology 2005; 65(8): 1306–8PubMedCrossRef
80.
Parmar BS, Shah KH, Gandhi IC. Baclofen in trigeminal neuralgia: a clinical trial. Indian J Dent Res 1989; 1: 109–13PubMed
81.
Steardo L, Leo A, Marano E. Efficacy of baclofen in trigeminal neuralgia and some other painful conditions: a clinical trial. Eur Neurol 1984; 23: 51–5PubMedCrossRef
82.
Fusco BM, Alessandri M. Analgesic effect of capsaicin in idiopathic trigeminal neuralgia. Anesth Analg 1992; 74: 375–7PubMedCrossRef
83.
Broggi G, Ferroli P, Franzini A, et al. Microvascular decompression for trigeminal neuralgia: comments on a series of 250 cases, including 10 patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68: 59–64PubMedCrossRef
84.
Broggi G, Ferroli P, Franzini A, et al. Operative findings and outcomes of microvascular decompression for trigeminal neuralgia in 35 patients affected by multiple sclerosis. Neurosurgery 2004; 55(4): 830–8, discussion 838-9PubMedCrossRef
85.
Athanasiou TC, Patel NK, Renowden SA, et al. Some patients with multiple sclerosis have neurovascular compression causing their trigeminal neuralgia and can be treated effectively with MVD: report of five cases. Br J Neurosurg 2005; 19(6): 463–8PubMedCrossRef
86.
Kondziolka D, Lunsford L, Flickinger J. Stereotactic radiosurgery for the treatment of trigeminal neuralgia. Clin J Pain 2002; 18: 42–7PubMedCrossRef
87.
Lim M, Villavicencio AT, Burneikiene S, et al. CyberKnife radiosurgery for idiopathic trigeminal neuralgia. Neurosurg Focus 2005 May 15; 18(5): E9PubMedCrossRef
88.
Henson CF, Goldman HW, Rosenwasser RH, et al. Glycerol rhizotomy versus gamma knife radiosurgery for the treatment of trigeminal neuralgia: an analysis of patients treated at one institution. Int J Radiat Oncol Biol Phys 2005; 63(1): 82–90PubMedCrossRef
89.
Cheng JS, Sanchez-Mejia RO, Limbo M, et al. Management of medically refractory trigeminal neuralgia in patients with multiple sclerosis. Neurosurg Focus 2005; 18(5): E13PubMedCrossRef
90.
91.
Garcia-Callejo FJ, Velert-Vila MM, Talamantes-Escriba F, et al. Clinical response of gabapentin for glossopharyngeal neuralgia [in Spanish]. Rev Neurol 1999; 28(4): 380–4PubMed
92.
Guido M, Specchio LM. Glossopharyngeal neuralgia responding to pregabalin. Headache 2006; 46(8): 1307–8PubMedCrossRef
93.
Espir ML, Millac P. Treatment of paroxysmal disorders in multiple sclerosis with carbamazepine (Tegretol). J Neurol Neurosurg Psychiatry 1970; 33: 528–31PubMedCrossRef
94.
Twomey JA, Espir MLE. Paroxysmal symptoms as the first manifestations of multiple sclerosis. J Neurol Neurosurg Psychiatry 1980; 43: 296–304PubMedCrossRef
95.
Cianchetti C, Zuddas A, Randazzo AP, et al. Lamotrigine adjunctive therapy in painful phenomena in MS: preliminary observations. Neurology 1999; 53: 433PubMedCrossRef
96.
Voiculescu V, Pruskauer-Apostol B, Alecu C. Treatment with acetazolamide of brain-stem and spinal paroxysmal disturbances in multiple sclerosis. J Neurol Neurosurg Psychiatry 1975; 38: 191–3PubMedCrossRef
97.
98.
Shibasaki H, Kuroiwa Y. Painful tonic seizures in multiple sclerosis. Arch Neurol 1974; 30: 47–51PubMedCrossRef
99.
Spissu A, Cannas A, Ferrigno P, et al. Anatomic correlates of painful tonic spasms in multiple sclerosis. Mov Disord 1999; 14: 331–5PubMedCrossRef
100.
Libenson MH, Stafstrom CE, Rosman NP. Tonic “seizures” in a patient with brainstem demyelination: a MRI study of brain and spinal cord. Pediatr Neurol 1994; 11: 258–62PubMedCrossRef
101.
Kuroiwa Y, Shibasaki H. Painful tonic seizure in multiple sclerosis: treatment with diphenylhydantoin and carbamazepine. Folia Pychiatr Neurol Jap 1968; 22: 107–19
102.
Sakurai M, Kanazawa I. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. J Neurol Sci 1999; 162: 162–8PubMedCrossRef
103.
Okada S, Kinoshita M, Fujioka T, et al. Two cases of multiple sclerosis with painful tonic seizures and dysesthesia ameliorated by the administration of mexiletine. Jpn J Med 1991; 30: 373–5PubMedCrossRef
104.
Galer BS, Harle J, Rowbotham MC. Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study. J Pain Symptom Manage 1996; 12: 161–7PubMedCrossRef
105.
Solaro C, Tanganelli P. Tiagabine for treating painful tonic spasms in multiple sclerosis: a pilot study [letter]. J Neurol Neurosurg Psychiatry 2004; 75(2): 341PubMed
106.
Sethi KD, Hess DC, Huffnagle VH, et al. Acetazolamide treatment of paroxysmal dystonia in central demyelinating disease. Neurology 1992; 42: 919–21PubMedCrossRef
107.
Vermote R, Ketelaer P, Carton H. Pain in multiple sclerosis patients. Clin Neurol Neurosurg 1986; 88: 87–92PubMedCrossRef
108.
Brochet B, Michel P, Henry P. Pain complaints in outpatients with multiple sclerosis: description and consequences on disability. Pain Clinic 1992; 5: 157–64
109.
110.
111.
Svendsen KB, Jensen TS, Hansen HJ, et al. Sensory function and quality of life in patients with multiple sclerosis and pain. Pain 2005; 114(3): 473–81PubMedCrossRef
112.
Feneberg W, Meister H, Pöllmann W. Dysesthesias and pain: a multidisciplinary treatment concept [in German]. In: Wötzel C, Wehner C, Pöllmann W, et al. editors. Therapy of multiple sclerosis. 2nd ed. Munich: Pflaum, 2000: 132–8
113.
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2005 Jul 20; (3): CD005454
114.
Backonja M. Anticonvulsants for the treatment of neuropathic pain syndromes. Curr Pain Headache Rep 2003 Feb; 7(1): 39–42PubMedCrossRef
115.
Finnerup NB, Gottrup H, Jensen TS. Anticonvulsants in central pain. Expert Opin Pharmacother 2002; 3: 1411–20PubMedCrossRef
116.
Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003; 60(11): 1524–34PubMedCrossRef
117.
Wiffen PJ, McQuay HJ, Edwards JE, et al. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev 2005 Jul 20; (3): CD005452
118.
Houtchens MK, Richert JR, Sami A, et al. Open label gabapentin treatment for pain in multiple sclerosis. Mult Scler 1997; 3: 250–3PubMedCrossRef
119.
Samkoff LM, Daras M, Tuchman AJ, et al. Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin. Neurology 1997; 49: 304–5PubMedCrossRef
120.
Chandra K, Shafiq N, Pandhi P, et al. Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial. The GONIP Trial. Int J Clin Pharmacol Ther 2006; 44(8): 358–63
121.
Vestergaard K, Andersen G, Gottrup H, et al. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology 2001; 56: 184–90PubMedCrossRef
122.
Eisenberg E, Lurie Y, Braker C, et al. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 2001; 57(3): 505–9PubMedCrossRef
123.
Vinik AI, Tuchman M, Safirstein B, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain 2007 Mar; 128(1-2): 169–79PubMedCrossRef
124.
McCleane G. Lamotrigine can reduce neurogenic pain associated with multiple sclerosis. Clin J Pain 1998; 14: 269–70PubMedCrossRef
125.
Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004; 110(3): 628–38PubMedCrossRef
126.
Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebocontrolled clinical trial. The 1008-045 Study Group. Pain 2004; 109(1-2): 26–35PubMedCrossRef
127.
Dworkin RH, Corbin AE, Young Jr JP, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebocontrolled trial. Neurology 2003; 60(8): 1274–83PubMedCrossRef
128.
Siddall PJ, Cousins MJ, Otte A, et al. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebocontrolled trial. Neurology 2006; 67(10): 1792–800PubMedCrossRef
129.
Vranken JH, Dijkgraaf MG, Kruis MR, et al. Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain 2007 Aug 17 [Epub ahead of print]
130.
Wallin J, Cui JG, Yakhnitsa V, et al. Gabapentin and pregabalin suppress tactile allodynia and potentiate spinal cord stimulation in a model of neuropathy. Eur J Pain 2002; 6(4): 261–72PubMedCrossRef
131.
Wernicke JF, Pritchett YL, D’Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006; 67(8): 1411–20PubMedCrossRef
132.
Silver M, Blum D, Grainger J, et al. Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain. J Pain Symptom Manage 2007 Oct; 34(4): 446–54PubMedCrossRef
133.
Breuer B, Pappagallo M, Knotkova H, et al. A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. Clin Ther 2007; 29(9): 2022–30PubMedCrossRef
134.
Mason L, Moore RA, Derry S, et al. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004; 328: 991–4PubMedCrossRef
135.
Davies PS, Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 2004; 64(9): 937–47PubMedCrossRef
136.
Gilron I, Watson CP, Cahill CM, et al. Neuropathic pain: a practical guide for the clinician. CMAJ 2006; 175(3): 265–75PubMedCrossRef
137.
Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev 2006 Jul 19; (3): CD006146
138.
Hollingshead J, Dühmke RM, Cornblath DR. Tramadol for neuropathic pain. Cochrane Database Syst Rev 2006 Jul 19; (3): CD003726
139.
Sittl R. Transdermal buprenorphine in the treatment of chronic pain. Expert Rev Neurother 2005; 5(3): 315–23PubMedCrossRef
140.
Likar R, Sittl R. Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies. Anesth Analg 2005 Mar; 100(3): 781–785PubMedCrossRef
141.
Dellemijn PL, van Duijn H, Vanneste JA. Prolonged treatment with transdermal fentanyl in neuropathic pain. J Pain Symptom Manage 1998 Oct; 16(4): 220–9PubMedCrossRef
142.
Agarwal S, Polydefkis M, Block B, et al. Transdermal fentanyl reduces pain and improves functional activity in neuropathic pain states. Pain Med 2007; 8(7): 554–62PubMedCrossRef
143.
Kaiman S, Osterberg A, Sorensen J, et al. Morphine responsiveness in a group of well-defined multiple sclerosis patients: a study with i.V. morphine. Eur J Pain 2002; 6: 69–80CrossRef
144.
Attal N, Guirimand F, Brasseur L, et al. Effects of IV morphine in central pain. Neurology 2002; 58: 554–63PubMedCrossRef
145.
Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002; 59: 1015–21PubMedCrossRef
146.
Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005; 352(13): 1324–34PubMedCrossRef
147.
Wade DT, Robson P, House H, et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 21–9PubMedCrossRef
148.
Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. UK MS Research Group. Lancet 2003; 362(9395): 1517–26PubMedCrossRef
149.
Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised, double-blind, placebo controlled, crossover trial. BMJ 2004; 329(7460): 253PubMedCrossRef
150.
Iskedjian M, Bereza B, Gordon A, et al. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 2007 Jan; 23(1): 17–24PubMedCrossRef
151.
Rog DJ, Nurmikko TJ, Young CA. Oromucosal Delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 2007; 29(9): 2068–79PubMedCrossRef
152.
Raskin P, Donofrio PD, Rosenthal NR, et al. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. CAPSS-141 Study Group. Neurology 2004; 63(5): 865–73
153.
Laughlin TM, Tram KV, Wilcox GL, et al. Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception. J Pharmacol Exp Ther 2002; 302: 1168–75PubMedCrossRef
154.
Novak V, Kanard R, Kissel JT, et al. Treatment of painful sensory neuropathy with tiagabine: a pilot study. Clin Auton Res 2001; 11(6): 357–61PubMedCrossRef
155.
Mattia C, Paoletti F, Coluzzi F, et al. New antidepressants in the treatment of neuropathic pain: a review. Minerva Anestesiol 2002; 68(3): 105–14PubMed
156.
Sindrup SH, Bach FW, Madsen C, et al. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003; 60: 1284–9PubMedCrossRef
157.
Schüler P, Seibel K, Chevts V, et al. Analgesic effect of the selective noradrenaline reuptake inhibitor reboxetine [in German]. Nervenarzt 2002; 73(2): 149–54PubMedCrossRef
158.
Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesth Analg 2003; 97: 1730–9PubMedCrossRef
159.
Sjölund BH. Pain and rehabilitation after spinal cord injury: the case of sensory spasticity? Brain Res Brain Res Rev 2002; 40(1-3): 250–6PubMedCrossRef
160.
Eide PK, Jorum E, Stubhaug A, et al. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo. Pain 1994 Sep; 58(3): 347–54PubMedCrossRef
161.
Sakai T, Tomiyasu S, Ono T, et al. Multiple sclerosis with severe pain and allodynia alleviated by oral ketamine. Clin J Pain 2004; 20(5): 375–6PubMedCrossRef
162.
Chiba S, Ito M, Matsumoto H. Amantadine treatment for refractory pain and fatigue in patients with multiple sclerosis [letter]. Can J Neurol Sci 1992; 19: 309PubMed
163.
Otto M, Bach FW, Jensen TS, et al. Valproic acid has no effect on pain in polyneuropathy: a randomized, controlled trial. Neurology 2004; 62: 285–8PubMedCrossRef
164.
Thienel U, Neto W, Schwabe SK, et al. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Topiramate Diabetic Neuropathic Pain Study Group. Acta Neurol Scand 2004 Oct; 110(4): 221–31PubMedCrossRef
165.
Nix WA. What is certain in pain therapy? The analgesic potency of neuroleptics in the treatment of chronic pain: a meta analysis [in German]. Schmerz 1998; 12: 30–8PubMedCrossRef
166.
Herman RM, D’Luzansky SC, Ippolito R. Intrathecal baclofen suppresses central pain in patients with spinal lesions: a pilot study. Clin J Pain 1992; 8: 338–45PubMedCrossRef
167.
Becker R, Uhle EI, Alberti O, et al. Continuous intrathecal baclofen infusion in the management of central deafferentation pain. J Pain Symptom Manage 2000; 20: 313–5PubMedCrossRef
168.
Paice JA, Penn RD, Kroin JS. Intrathecal octreotide for relief of intractable nonmalignant pain: 5-year experience with two cases. Neurosurgery 1996; 38: 203–7PubMedCrossRef
169.
Birknes JK, Sharan A, Rezai AR. Treatment of chronic pain with neurostimulation. Prog Neurol Surg 2006; 19: 197–207PubMedCrossRef
170.
Graff-Radford SB, Shaw LR, Naliboff BN. Amitriptyline and fluphenazine in the treatment of postherpetic neuralgia. Clin J Pain 2000; 16: 188–92PubMedCrossRef
171.
Frese A, Husstedt IW, Ringelstein EB, et al. Pharmacologic treatment of central post-stroke pain. Clin J Pain 2006; 22(3): 252–60PubMedCrossRef
172.
173.
174.
175.
176.
Klewer J, Pöhlau D, Nippert I, et al. Problems reported by elderly patients with multiple sclerosis. J Neurosci Nurs 2001; 33: 167–71PubMedCrossRef
177.
Wötzel C, Wehner C, Pöllmann W, et al., editors. Therapy of multiple sclerosis [in German].2nded.Munich: Pflaum, 2000: 1–230
178.
Haselkorn JK, Balsdon Richer C, Fry Welch D, et al. Multiple Sclerosis Council for Clinical Practice guidelines. Overview of spasticity management in multiple sclerosis: evidence-based management strategies for spasticity treatment in multiple sclerosis. J Spinal Cord Med 2005; 28(2): 167–99PubMed
179.
Khan F, Turner-Stokes L, Ng L, et al. Multidisciplinary rehabilitation for adults with multiple sclerosis. Cochrane Database Syst Rev 2007 Apr 18; (2): CD 006036.
180.
Rietberg MB, Brooks D, Uitdehaag BM, et al. Exercise therapy for multiple sclerosis. Cochrane Database Syst Rev 2005 Jan 25; (1): CD003980
181.
Rietberg MB, Brooks D, Uitdehaag BMJ, et al. Exercise therapy for multiple sclerosis. Cochrane Database of Systematic Reviews 2004; (3): CD003980
182.
Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987 Feb; 67(2): 206–7.PubMed
183.
Allison SC, Abraham LD. Sensitivity of qualitative and quantitative spasticity measures to clinical treatment with cryotherapy. Int J Rehabil Res 2001 Mar; 24(1): 15–24PubMedCrossRef
184.
Miller L, Mattison P, Paul L, et al. The effects of transcutaneous electrical nerve stimulation (TENS) on spasticity in multiple sclerosis. Mult Scler 2007 May; 13(4): 527–33PubMed
185.
Rizzo MA, Hadjimichael OC, Preiningerova J, et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004 Oct; 10(5): 589–95PubMedCrossRef
186.
Sachais BA, Logue JN, Carey MS. Baclofen, a new antispastic drug: a controlled, multicenter trial in patients with multiple sclerosis. Arch Neurol 1977; 34: 422–8PubMedCrossRef
187.
188.
Shakespeare D, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003; (4): CD001332
189.
Mueller ME, Gruenthal M, Olson WL, et al. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil 1997; 78: 521–4PubMedCrossRef
190.
Solaro C, Uccelli MM, Guglieri P, et al. Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. Mult Scler 2000; 6: 192–3PubMed
191.
Cutter NC, Scott DD, Johnson JC, et al. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomised trial. Arch Phys Med Rehabil 2000; 81: 164–9PubMed
192.
Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculo-skeletal conditions: a systematic review. J Pain Symptom Manage 2004; 28(2): 140–75PubMedCrossRef
193.
Schapiro RT. Management of spasticity, pain, and paroysmal phenomena in multiple sclerosis. Curr Neurol Neurosci Reports 2001; 1: 299–302CrossRef
194.
Hawker K, Frohman E, Racke M. Levetiracetam for phasic spasticity in multiple sclerosis. Arch Neurol 2003; 60: 1772–4PubMedCrossRef
195.
Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004; 10: 417–24PubMedCrossRef
196.
Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10: 434–41PubMedCrossRef
197.
Wissel J, Haydn T, Muller J, et al. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol 2006 Oct; 253(10): 1337–41PubMedCrossRef
198.
Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006; 12(5): 639–45PubMedCrossRef
199.
Lang AM. Botulinum toxin type A therapy in chronic pain disorders. Arch Phys Med Rehabil 2003; 84(3 Suppl. 1): S69–73PubMedCrossRef
200.
201.
Wissel J, Muller J, Dressnandt J, et al. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 2000; 20: 44–9PubMedCrossRef
202.
Mancini F, Sandrini G, Moglia A, et al. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci 2005; 26(1): 26–31PubMedCrossRef
203.
Chalkiadaki A, Rohr UP, Hefter H. Early pain reduction in the treatment of spasticity after a single injection of botulinum A toxin [in German]. Dtsch Med Wochenschr 2001; 126: 1361–4PubMedCrossRef
204.
Cardoso E, Rodrigues B, Lucena R, et al. Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysis. Arq Neuropsiquiatr 2005; 63(1): 30–3PubMedCrossRef
205.
Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000; 68(6): 707–12PubMedCrossRef
206.
Dario A, Scamoni C, Bono G, et al. Functional improvement in patients with severe spinal spasticity treated with chronic intrathecal baclofen infusion. Funct Neurol 2001; 16: 311–5PubMed
207.
Middel B, Kuipers-Upmeijer H, Bouma J, et al. Effect of intrathecal baclofen delivered by an implanted programmable pump on health-related quality of life in patients with severe spasticity. J Neurol Neurosurg Psychiatry 1997; 63: 204–9PubMedCrossRef
208.
Ochs A, Tonn JC. Functional outcome and clinical significance of long-term intrathecal baclofen therapy for severe spasticity. J Neuro Rehab 1996; 10: 159–66
209.
Dahm PO, Nitescu PV, Appelgren LK, et al. Long-term intrathecal (i.t.) infusion of bupivacaine relieved intractable pain and spasticity in a patient with multiple sclerosis. Eur J Pain 1998; 2: 81–5PubMedCrossRef
210.
Jarrett L, Nandi P, Thompson AJ. Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role? J Neurol Neurosurg Psychiatry 2002; 73: 705–9PubMedCrossRef
211.
Heun R, Emser W, Schimrigk K. Evoked potentials under intrathecal and systemic corticosteroid application in patients with multiple sclerosis [in German]. Z EEG-EMG 1987; 20: 88–91
212.
Hoffmann V, Schimrigk S, Islamova S, et al. Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients. J Neurol Sci 2003; 211: 81–4PubMedCrossRef
213.
Salame K, Ouaknine GE, Rochkind S, et al. Surgical treatment of spasticity by selective posterior rhizotomy: 30 years experience. Isr Med Assoc J 2003; 5(8): 543–6PubMed
214.
Penn RD. Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J Neurosurg 1992 Aug; 77(2): 236–40.PubMedCrossRef
215.
Gibson J, Frank A. Pain experienced by electric-powered chair users: a pilot exploration using pain drawings. Physiother Res Int 2005; 10(2): 110–5PubMedCrossRef
216.
Philadelphia Panel. Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for neck pain. Phys Ther 2001; 81: 1701–17
217.
Philadelphia Panel. Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for shoulder pain. Phys Ther 2001; 81: 1719–30
218.
Philadelphia Panel. Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for knee pain. Phys Ther 2001; 81: 1675–700
219.
Feine JS, Lund JP. An assessment of the efficacy of physical therapy and physical modalities for the control of chronic musculoskeletal pain. Pain 1997; 71: 5–23PubMedCrossRef
220.
Korthals-de Bos IB, Hoving JL, van Tulder MW, et al. Cost effectiveness of physiotherapy, manual therapy, and general practitioner care for neck pain: economic evaluation alongside a randomised controlled trial. BMJ 2003; 326: 911PubMed
221.
222.
Turner-Stokes L, Jackson D. Shoulder pain after stroke: a review of the evidence base to inform the development of an integrated care pathway. Clin Rehabil 2002; 16: 276–98PubMedCrossRef
223.
Lim JY, Koh JH, Paik NJ. Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: a randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide. Stroke 2008 Jan; 39(1): 126–31PubMedCrossRef
224.
Kidd BL, Langford RM, Wodehouse T. Arthritis and pain: current approaches in the treatment of arthritic pain. Arthritis Res Ther 2007; 9(3): 214PubMedCrossRef
225.
Schnitzer TJ. Update on guidelines for the treatment of chronic musculoskeletal pain. Clin Rheumatol 2006; 25Suppl. 1: 22–9CrossRef
226.
Towheed TE, Maxwell L, Judd MG, et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006; (1): CD004257
227.
Jalan R, Williams R, Bernuau J. Paracetamol: are therapeutic doses entirely safe? Lancet 2006 Dec 23; 368(9554): 2195–6PubMedCrossRef
228.
Porcheret M, Jordan K, Croft P. Treatment of knee pain in older adults in primary care: development of an evidence-based model of care. Primary Care Rhumatology Society. Rheumatology (Oxford) 2007; 46(4): 638–48CrossRef
229.
Qerama E, Fuglsang-Frederiksen A, Kasch H, et al. A double-blind, controlled study of botulinum toxin A in chronic my-ofascial pain. Neurology 2006 Jul 25; 67(2): 241–5PubMedCrossRef
230.
Albrecht H, Pöllmann W, König N. Acute foot drop paralysis in multiple sclerosis: peroneal nerve compression as differential diagnosis of acute onset [in German]. Nervenarzt 1996; 67: 163–9PubMed
231.
Henze T, Rieckmann P, Toyka KV. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol 2006; 56(2): 85–7CrossRef
232.
Henze T, Rieckmann P, Toyka KV. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol 2006; 56(2): 87–8CrossRef
233.
Brochet B, Lemaire G, Beddiaf A. Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices [in French]. l’Epicure Study Group. Rev Neurol (Paris) 2006; 162(6-7): 735–40PubMedCrossRef
234.
Buhse M. Efficacy of EMLA cream to reduce fear and pain associated with interferon beta-1a injection in patients with multiple sclerosis. J Neurosci Nurs 2006; 38(4): 222–6PubMedCrossRef
235.
Neilley LK, Goodin DS, Goodkin DE, et al. Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology 1996; 46: 552–4PubMedCrossRef
236.
Reess J, Haas J, Gabriel K, et al. Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX) therapy. Mult Scler 2002; 8: 15–8PubMed
237.
Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 1999 Nov 10; 53(8): 1622–7PubMedCrossRef
238.
Rio J, Nos C, Bonaventura I, et al. Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial. Neurology 2004; 63(3): 525–8PubMedCrossRef
239.
Leuschen MP, Filipi M, Healey K. A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFN beta-1a therapy and during its ongoing use for relapsing-remitting multiple sclerosis. Mult Scler 2004 Dec; 10(6): 636–42PubMedCrossRef
240.
Pöllmann W, Erasmus L-P, Feneberg W, et al. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS. Neurology 2002; 59: 636–9PubMedCrossRef
241.
Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine: report of an EFNS task force. Eur J Neurol 2006; 13(6): 560–72PubMedCrossRef
242.
Soos N, Shakery K, Mrowietz U. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis. Am J Clin Dermatol 2004; 5(5): 357–9PubMedCrossRef
243.
Pöllmann W, Erasmus LP, Feneberg W, et al. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS. Neurology 2006; 66(2): 275–7PubMedCrossRef
244.
Katz U, Kishner I, Magalashvili D, et al. Long-term safety of IVIg therapy in multiple sclerosis: 10 years experience. Autoimmunity 2006 Sep; 39(6): 513–7PubMedCrossRef
245.
Finkel AG, Howard JF, Mann JD. Successful treatment of headache related to intravenous immunglobulin with antimigraine medication. Headache 1998; 38: 317–21PubMedCrossRef
246.
Koes BW, van Tulder MW, Thomas S. Diagnosis and treatment of low back pain. BMJ 2006; 332(7555): 1430–4PubMedCrossRef
247.
van Tulder M, Becker A, Bekkering T, et al. European guidelines for the management of acute nonspecific low back pain in primary care (chapter 3). The COST B13 Working Group on Guidelines for the Management of Acute Low Back Pain in Primary Care. Eur Spine J 2006 Mar; 15Suppl. 2: S169–91PubMedCrossRef
248.
Philadelphia Panel. Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for low back pain. Phys Ther 2001; 81: 1641–74
249.
Hayden JA, van Tulder MW, Malmivaara A, et al. Exercise therapy for treatment of non-specific low back pain. Cochrane Database Syst Rev 2005 Jul 20; (3): CD000335
250.
Khadilkar A, Milne S, Brosseau L, et al. Transcutaneous electrical nerve stimulation for the treatment of chronic low back pain: a systematic review. Spine 2005; 30(23): 2657–66PubMedCrossRef
251.
Al-Smadi J, Warke K, Wilson I, et al. A pilot investigation of the hypoalgesic effects of transcutaneous electrical nerve stimulation upon low back pain in people with multiple sclerosis. Clin Rehabil 2003; 17: 742–9PubMedCrossRef
252.
Warke K, Al-Smadi J, Baxter D, et al. Efficacy of transcutaneous electrical nerve stimulation (tens) for chronic low-back pain in a multiple sclerosis population: a randomized, placebo-controlled clinical trial. Clin J Pain 2006; 22(9): 812–9PubMedCrossRef
253.
Airaksinen O, Brox JI, Cedraschi C, et al. European guidelines for the management of chronic nonspecific low back pain. The COST B13 Working Group on Guidelines for Chronic Low Back Pain. Eur Spine J 2006 Mar; 15Suppl. 2: S192–300PubMedCrossRef
254.
Kalso E, Allan L, Dobrogowski J, et al. Do strong opioids have a role in the early management of back pain? Recommendations from a European expert panel. Curr Med Res Opin 2005; 21(11): 1819–28PubMedCrossRef
255.
Foster L, Clapp L, Erickson M, et al. Botulinum toxin A and chronic low back pain: a randomised, double-blind study. Neurology 2001; 56: 1290–3PubMedCrossRef
256.
Leibing E, Leonhardt U, Koster G, et al. Acupuncture treatment of chronic low-back pain: a randomized, blinded, placebo-controlled trial with 9-month follow-up. Pain 2002; 96: 189–96PubMedCrossRef
257.
Ramirez-Lassepas M, Tulloch JW, et al. Acute radicular pain as a presenting symptom in multiple sclerosis. Arch Neurol 1992; 49: 255–8PubMedCrossRef
258.
Portenoy RK, Yang K, Thorton D. Chronic intractable pain: an atypical presentation of multiple sclerosis. J Neurol 1988; 235: 226–8PubMedCrossRef
259.
Armingeat T, Brondino R, Pham T, et al. Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study. Osteoporos Int 2006; 17(11): 1659–65PubMedCrossRef
260.
Goemaere S, Van Laere M, De Neve P, et al. Bone mineral status in paraplegic patients who do or do not perform standing. Osteoporos Int 1994; 4: 138–43PubMedCrossRef
261.
La Mantia L, D’Amico D, Rigamonti A, et al. Interferon treatment may trigger primary headaches in multiple sclerosis patients. Mult Scler 2006; 12(4): 476–80PubMedCrossRef
262.
Rasmussen BK. Epidemiology of headache. Cephalalgia 1995; 15: 45–68PubMed
263.
Lampl C, Buzath A, Baumhackl U, et al. One-year prevalence of migraine in Austria: a nation-wide survey. Cephalalgia 2003; 23: 280–6PubMedCrossRef
264.
Freedman MS, Gray TA. Vascular headache: a presenting symptom of multiple sclerosis. Can J Neurol Sci 1989; 16: 63–6PubMed
265.
Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nature Med 1995; 1(7): 658–60PubMedCrossRef
266.
Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society [summary for patients in Ann Intern Med 2007 Oct 2; 147(7): 145]. Clinical Efficacy Assessment Subcommittee of the American College of Physicians, American College of Physicians, American Pain Society Low Back Pain Guidelines Panel. Ann Intern Med 2007 Oct 2; 147(7): 478–91PubMed
Metadata
Title
Current Management of Pain Associated with Multiple Sclerosis
Authors
Dr Walter Pöllmann
Wolfgang Feneberg
Publication date
01-04-2008
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 4/2008
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200822040-00003

Other articles of this Issue 4/2008

CNS Drugs 4/2008 Go to the issue

Original Research Article

Pregnancy Outcome after In Utero Exposure to Valproate

Adis Drug Evaluation

Intramuscular Aripiprazole

Current Opinion

Use of Smoking Cessation Therapies in Individuals with Psychiatric Illness

Review Article

Assessing the Efficacy of Treatments for ADHD